Semax is not discussed in the abstract; the paper reviews central effects of antiviral and immunomodulatory drugs.

The complex interplay between the nervous and immune systems, often called neuro-immune interaction, presents a significant challenge and opportunity in pharmacology. Traditional drug development often focuses on a single system, but evidence shows that pharmacological agents targeting one system frequently have unintended or unexplained effects on the other. For instance, drugs designed for antiviral or immunomodulatory purposes can produce profound central nervous system side effects like depression or psychosis. Conversely, psychotropic drugs can alter immune function. This review seeks to systematize the understanding of these cross-system effects to improve drug design, enhance efficacy, and increase safety by analyzing the mechanisms that link central effects (like neurogenesis and neuron survival) with peripheral immune responses (like changes in proinflammatory cytokines).

This paper is a literature review, not a primary experimental study. The authors conducted a systematic analysis of published experimental and clinical data to explore the pharmacological effects of drugs at different levels of biological organization. They focused specifically on psychotropic, antiviral, and immunomodulatory drugs. The primary goal was to identify and analyze the correlation between the central effects of these drugs—particularly their impact on adult brain neurogenesis and neuronal survival—and their ability to modulate the levels of key proinflammatory cytokines. The review synthesized information from various sources to understand the integrative mechanisms underlying neuro-immune interactions and explain the "pleiotropic" pharmacological effects observed with these agents.

The analysis of published data revealed a clear correlation between the central nervous system effects of various drugs and their immunomodulatory properties. Altering one system with a pharmacological agent inevitably leads to functional reorganization in the other. Several examples illustrate this link: the antiviral drug Amantadine was later approved as an anti-parkinsonian drug. Interferon alpha, an immunomodulator, causes significant depression in a large subset of patients, limiting its clinical utility.

The prolonged administration of interferon alpha caused depression in 30-45% of patients, thus limiting its clinical use. The antiviral medication Oseltamivir can trigger severe central side effects, including abnormal behavior, delirium, and suicidal ideation. Conversely, the anti-herpetic drug Panavir was found to exhibit pronounced neuroprotective properties. These findings collectively demonstrate that the pharmacological effects previously considered distinct are often linked through integrated neuro-immune pathways, where changes in proinflammatory cytokines are associated with significant alterations in brain function and neuronal health.

Written by TitrateLab, separately from the study summarized above.